Compare CHH & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHH | APLS |
|---|---|---|
| Founded | 1939 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.2B |
| IPO Year | 1997 | 2015 |
| Metric | CHH | APLS |
|---|---|---|
| Price | $116.84 | $40.85 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 21 |
| Target Price | ★ $109.70 | $32.71 |
| AVG Volume (30 Days) | 474.9K | ★ 8.2M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | 27.42 | ★ 112.50 |
| EPS | ★ 7.90 | 0.20 |
| Revenue | ★ $1,596,793,000.00 | $1,003,782,000.00 |
| Revenue This Year | $66.74 | N/A |
| Revenue Next Year | $0.37 | $18.19 |
| P/E Ratio | ★ $14.82 | $204.28 |
| Revenue Growth | 0.75 | ★ 28.46 |
| 52 Week Low | $84.04 | $16.10 |
| 52 Week High | $136.45 | $40.88 |
| Indicator | CHH | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 71.58 | 87.65 |
| Support Level | $92.66 | $18.53 |
| Resistance Level | $136.17 | N/A |
| Average True Range (ATR) | 3.49 | 0.23 |
| MACD | 1.77 | 0.99 |
| Stochastic Oscillator | 88.12 | 99.90 |
At year-end 2025, Choice Hotels operated 657,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (27% of the company's total rooms), while Ascend and Cambria (10%) are lifestyle and select-service brands, and WoodSpring (5%) is the company's largest extended-stay brand. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2024.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).